Cancers,
Journal Year:
2023,
Volume and Issue:
15(6), P. 1697 - 1697
Published: March 10, 2023
T
cell
immunoglobulin
and
mucin
domain
3
(TIM-3)
is
an
inhibitory
immunocheckpoint
that
belongs
to
the
TIM
gene
family.
Monney
et
al.
first
discovered
it
about
20
years
ago
linked
some
autoimmune
diseases;
subsequent
studies
have
revealed
tumours,
including
melanoma,
capacity
produce
ligands
bind
these
receptor
checkpoints
on
tumour-specific
immune
cells.
We
conducted
a
literature
search
using
PubMed,
Web
of
Science
(WoS),
Scopus,
Google
Scholar,
Cochrane,
searching
for
following
keywords:
“T
mucin-domain
containing-3”,
“TIM-3”
and/or
“Immunocheckpoint
inhibitors”
in
combination
with
“malignant
melanoma”
or
“human
malignant
“cutaneous
melanoma”.
The
initially
turned
up
117
documents,
23
which
were
duplicates.
After
verifying
eligibility
inclusion
criteria,
17
publications
ultimately
included.
A
growing
body
scientific
evidence
considers
TIM-3
valid
immuno-checkpoint
very
interesting
potential
field
melanoma.
However,
other
recent
new
roles
seem
almost
contradict
previous
findings
this
regard.
All
demonstrates
how
common
concept
‘pleiotropism’
TME
field,
same
molecule
can
behave
completely
partially
differently
depending
type
considered
temporary
conditions.
Further
studies,
large
case
series,
special
focus
immunophenotype
are
absolutely
necessary
order
explore
highly
promising
topic
near
future.
Heliyon,
Journal Year:
2024,
Volume and Issue:
10(12), P. e32433 - e32433
Published: June 1, 2024
Numerous
studies
underscore
the
relevance
of
tumor-infiltrating-lymphocytes
(TILs)
as
important
prognostic
factors
for
melanoma.
This
meta-analysis
aims
to
provide
a
comprehensive
literature
overview
elucidating
their
role
in
predicting
patient
outcomes,
specifically
investigating
association
between
TIL
density
and
prognosis.
Experimental Dermatology,
Journal Year:
2024,
Volume and Issue:
33(6)
Published: June 1, 2024
Abstract
This
manuscript
presents
a
comprehensive
investigation
into
the
role
of
lactate
metabolism‐related
genes
as
potential
prognostic
markers
in
skin
cutaneous
melanoma
(SKCM).
Bulk‐transcriptome
data
from
The
Cancer
Genome
Atlas
(TCGA)
and
GSE19234,
GSE22153,
GSE65904
cohorts
GEO
database
were
processed
harmonized
to
mitigate
batch
effects.
Lactate
metabolism
scores
assigned
individual
cells
using
‘AUCell’
package.
Weighted
Co‐expression
Network
Analysis
(WGCNA)
was
employed
identify
gene
modules
correlated
with
metabolism.
Machine
learning
algorithms
applied
construct
model,
its
performance
evaluated
multiple
cohorts.
Immune
correlation,
mutation
analysis,
enrichment
analysis
conducted
further
characterize
model's
biological
implications.
Finally,
function
key
NDUFS7
verified
by
cell
experiments.
resulted
an
optimal
demonstrating
significant
value
across
various
In
different
cohorts,
high‐risk
group
showed
poor
prognosis.
indicated
differences
immune
infiltration
checkpoint
expression
between
risk
groups.
Mutation
identified
high
loads
SKCM.
Enrichment
unveiled
enriched
pathways
processes
SKCM
patients.
found
be
hub
protein–protein
interaction
network.
After
reduced
siRNA
knockdown,
CCK‐8,
colony
formation,
transwell
wound
healing
tests
that
activity,
proliferation
migration
A375
WM115
lines
significantly
decreased.
study
offers
insights
significance
Dermatopathology,
Journal Year:
2023,
Volume and Issue:
10(1), P. 91 - 92
Published: Feb. 13, 2023
Year
after
year,
the
incidence
and
prevalence
rates
of
cutaneous
Malignant
Melanoma
(MM)
show
a
continuous
increase
and,
according
to
most
up-to-date
American
Cancer
Society
(ACS)
projections,
it
is
estimated
that
97,610
new
melanomas
will
be
diagnosed
in
2023
(about
58,120
men
39,490
women)
approximately
7990
people
are
expected
die
melanoma
5420
2570
[...].
Pharmaceuticals,
Journal Year:
2023,
Volume and Issue:
16(5), P. 746 - 746
Published: May 14, 2023
This
study
aimed
to
synthesize
four
new
semisynthetic
derivatives
of
natural
oleanolic
acid
(OA)
and,
based
on
an
analysis
their
cytotoxic
and
anti-proliferative
effects
against
human
MeWo
A375
melanoma
cell
lines,
select
those
with
anti-cancer
potential.
We
also
screened
the
treatment
time
concentration
all
derivatives.
synthesized
oxime
2
performed
its
acylation
carboxylic
acids
into
3a,
3b,
3c
3d
according
methods
previously
described.
Colorimetric
MTT
SRB
assays
were
used
measure
activity
OA
cells.
Selected
concentrations
OA,
derivatives,
different
periods
incubation
in
study.
The
data
analyzed
statistically.
present
results
revealed
possible
potential
two
selected
3a
cells,
especially
at
50
μM
100
48
h
(p
<
0.05).
Further
studies
will
be
necessary
analyze
proapoptotic
activities
3b
skin
other
cancer
bromoacetoxyimine
derivative
(3b)
morpholide
turned
out
most
effective
tested
Molecules,
Journal Year:
2023,
Volume and Issue:
28(17), P. 6251 - 6251
Published: Aug. 25, 2023
Skin
cancer
is
a
condition
characterized
by
the
abnormal
growth
of
skin
cells,
primarily
caused
exposure
to
ultraviolet
(UV)
radiation
from
sun
or
artificial
sources
like
tanning
beds.
Different
types
include
melanoma,
basal
cell
carcinoma,
and
squamous
carcinoma.
Despite
advancements
in
targeted
therapies,
there
still
need
for
safer,
highly
efficient
approach
preventing
treating
cutaneous
malignancies.
Spices
have
rich
history
dating
back
thousands
years
are
renowned
their
ability
enhance
flavor,
taste,
color
food.
Derived
various
plant
parts
seeds,
fruits,
bark,
roots,
flowers,
spices
important
culinary
ingredients.
However,
value
extends
beyond
realm.
Some
contain
bioactive
compounds,
including
phenolic
which
known
significant
biological
effects.
These
compounds
attracted
attention
scientific
research
due
potential
health
benefits,
possible
role
disease
prevention
treatment,
such
as
cancer.
This
review
focuses
on
examining
spice-derived
preventive
therapeutic
agents
managing
cancers.
By
compiling
analyzing
available
knowledge,
this
aims
provide
insights
that
can
guide
future
identifying
new
anticancer
phytochemicals
uncovering
additional
mechanisms
combating
Cancers,
Journal Year:
2024,
Volume and Issue:
16(12), P. 2173 - 2173
Published: June 7, 2024
Cutaneous
malignant
melanoma
is
one
of
the
most
common
neoplasms
among
pregnancy-associated
cancers
(PACs).
Risk
factors
include
excessive
exposure
to
ultraviolet
radiation,
presence
benign
and
dysplastic
nevi,
a
patient
or
family
history
melanoma.
Self-examination
careful
inspection
nevi
are
crucial,
especially
in
context
their
progression
over
time.
Physiological
changes
that
occur
during
pregnancy,
such
as
darkening
enlargement
delay
diagnosis
CMM.
In
fetus,
metastases
very
rare,
if
they
do
occur,
concern
placenta
fetal
tissues.
The
choice
treatment
influenced
by
cancer
stage,
symptoms,
time
termination
patient’s
decision.
Essential
procedures
which
safe
for
fetus
diagnostic
biopsy,
ultrasound,
therapeutic
excision
lesion
affected
lymph
nodes.
Other
imaging
methods
can
be
used
with
radiation
dose
limit
100
mGy.
Immunotherapy
targeted
treatments
must
carefully
considered,
because
possible
adverse
effects
on
fetus.
An
interdisciplinary
approach
problem
pregnancy
necessary,
involving
doctors
various
specialties.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(19), P. 3260 - 3260
Published: Sept. 25, 2024
Immunotherapies,
including
checkpoint
inhibitor
antibodies,
have
precipitated
significant
improvements
in
clinical
outcomes
for
melanoma.
However,
approximately
half
of
patients
do
not
benefit
from
approved
treatments.
Additionally,
apart
Tebentafusp,
which
is
the
treatment
uveal
melanoma,
there
a
lack
immunotherapies
directly
focused
on
melanoma
cells.
This
partly
due
to
few
available
targets,
especially
those
expressed
cancer
cell
surface.
Chondroitin
sulfate
proteoglycan
4
(CSPG4)
surface
molecule
overexpressed
human
with
restricted
distribution
and
low
expression
non-malignant
tissues
involved
several
cancer-promoting
dissemination
pathways.
Here,
we
summarize
current
understanding
functional
significance
CSPG4
health
outline
immunotherapeutic
strategies.
These
include
monoclonal
antibody-drug
conjugates
(ADCs),
chimeric-antigen
receptor
(CAR)
T
cells,
other
strategies
such
as
anti-idiotypic
mimotope
vaccines
raise
immune
responses
against
CSPG4-expressing
melanomas.
Several
showed
promising
functions
preclinical
models
yet
reached
testing,
none
are
therapeutic
use.
Obstacles
preventing
that
progress
limited
knowledge
function
vivo
adequately
represent
patient
biology.
Despite
challenges,
immunotherapy
directed
harbors
potential
transform
landscape.
